Cancer deaths are higher among organ transplant recipients
the ONA take:
Transplant patients receive drugs to prevent rejection of the new organ; however, because those drugs suppress the patient’s immune system, they are more susceptible to cancers many years later.
In particular, transplant recipients in Australia have a high risk of skin cancer because of its high UV levels. Researchers at the University of Adelaide are working on understanding this risk and how cancers can be prevented in this population.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer.
The researchers note, however, that they as of yet have no real way of preventing those cancers from occurring. But in an effort to find a balance between ensuring transplanted organs are not rejected and reducing the risk of cancers in these patients, the research team is conducting further studies to determine what the impact reducing immunosuppressants will have on patients.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|